RU2010123028A - Кортикостероиды для лечения диареи, индуцированной эпотилоном или производным эпотилона - Google Patents
Кортикостероиды для лечения диареи, индуцированной эпотилоном или производным эпотилона Download PDFInfo
- Publication number
- RU2010123028A RU2010123028A RU2010123028/15A RU2010123028A RU2010123028A RU 2010123028 A RU2010123028 A RU 2010123028A RU 2010123028/15 A RU2010123028/15 A RU 2010123028/15A RU 2010123028 A RU2010123028 A RU 2010123028A RU 2010123028 A RU2010123028 A RU 2010123028A
- Authority
- RU
- Russia
- Prior art keywords
- epothilone
- treatment
- antidiarrheal agent
- patient
- derivative
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title claims abstract 4
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract 3
- 229960001334 corticosteroids Drugs 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 18
- 229940125714 antidiarrheal agent Drugs 0.000 claims abstract 17
- 239000003793 antidiarrheal agent Substances 0.000 claims abstract 17
- 150000003883 epothilone derivatives Chemical class 0.000 claims abstract 14
- 229960004618 prednisone Drugs 0.000 claims abstract 8
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims abstract 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract 7
- 239000003862 glucocorticoid Substances 0.000 claims abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 7
- 239000001257 hydrogen Substances 0.000 claims abstract 7
- 229930013356 epothilone Natural products 0.000 claims abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 4
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims abstract 3
- 229960003957 dexamethasone Drugs 0.000 claims abstract 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract 3
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims abstract 3
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical group C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 3
- 229960005205 prednisolone Drugs 0.000 claims abstract 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98663507P | 2007-11-09 | 2007-11-09 | |
| US60/986,635 | 2007-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010123028A true RU2010123028A (ru) | 2011-12-20 |
Family
ID=40087318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010123028/15A RU2010123028A (ru) | 2007-11-09 | 2008-10-15 | Кортикостероиды для лечения диареи, индуцированной эпотилоном или производным эпотилона |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100267682A1 (enExample) |
| EP (1) | EP2222286A1 (enExample) |
| JP (1) | JP2011503075A (enExample) |
| KR (1) | KR20100096077A (enExample) |
| CN (1) | CN101848708B (enExample) |
| AU (1) | AU2008325016A1 (enExample) |
| BR (1) | BRPI0820338A2 (enExample) |
| CA (1) | CA2703792A1 (enExample) |
| MX (1) | MX2010005119A (enExample) |
| RU (1) | RU2010123028A (enExample) |
| WO (1) | WO2009061587A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014052237A1 (en) | 2012-09-26 | 2014-04-03 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| EP2945628B1 (en) * | 2013-01-15 | 2020-04-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer |
| US11061027B2 (en) * | 2016-09-27 | 2021-07-13 | Mayo Foundation For Medical Education And Research | Materials and methods for evaluating and treating cancer |
| KR20240096623A (ko) | 2017-10-16 | 2024-06-26 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
| US10705435B2 (en) | 2018-01-12 | 2020-07-07 | Globalfoundries Inc. | Self-referencing and self-calibrating interference pattern overlay measurement |
| US11686576B2 (en) | 2020-06-04 | 2023-06-27 | Kla Corporation | Metrology target for one-dimensional measurement of periodic misregistration |
| US11796925B2 (en) | 2022-01-03 | 2023-10-24 | Kla Corporation | Scanning overlay metrology using overlay targets having multiple spatial frequencies |
| US12032300B2 (en) | 2022-02-14 | 2024-07-09 | Kla Corporation | Imaging overlay with mutually coherent oblique illumination |
| US12422363B2 (en) | 2022-03-30 | 2025-09-23 | Kla Corporation | Scanning scatterometry overlay metrology |
| US12487190B2 (en) | 2022-03-30 | 2025-12-02 | Kla Corporation | System and method for isolation of specific fourier pupil frequency in overlay metrology |
| US12669327B2 (en) | 2022-11-23 | 2026-06-30 | Kla Corporation | System and method for suppression of tool induced shift in scanning overlay metrology |
| US12235588B2 (en) | 2023-02-16 | 2025-02-25 | Kla Corporation | Scanning overlay metrology with high signal to noise ratio |
| US12704790B2 (en) | 2023-04-04 | 2026-08-11 | Kla Corporation | System and method for determining overlay measurement of a scanning target |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1231894A (zh) * | 1998-04-14 | 1999-10-20 | 陈水清 | 止泻栓 |
| EP1372650B1 (en) * | 2001-03-19 | 2008-11-19 | Novartis AG | Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| US6974818B2 (en) * | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
| AU2003264822A1 (en) * | 2002-10-11 | 2004-05-04 | Dana-Farber Cancer Institute Inc | Epothilone derivatives for the treatment of multiple myeloma |
| BRPI0513825A (pt) * | 2004-07-26 | 2008-05-20 | Novartis Ag | combinações de epotilona |
-
2008
- 2008-10-15 BR BRPI0820338A patent/BRPI0820338A2/pt not_active IP Right Cessation
- 2008-10-15 WO PCT/US2008/079936 patent/WO2009061587A1/en not_active Ceased
- 2008-10-15 MX MX2010005119A patent/MX2010005119A/es not_active Application Discontinuation
- 2008-10-15 RU RU2010123028/15A patent/RU2010123028A/ru not_active Application Discontinuation
- 2008-10-15 CA CA2703792A patent/CA2703792A1/en not_active Abandoned
- 2008-10-15 KR KR1020107010102A patent/KR20100096077A/ko not_active Withdrawn
- 2008-10-15 JP JP2010533139A patent/JP2011503075A/ja active Pending
- 2008-10-15 AU AU2008325016A patent/AU2008325016A1/en not_active Abandoned
- 2008-10-15 CN CN2008801149548A patent/CN101848708B/zh not_active Expired - Fee Related
- 2008-10-15 US US12/741,680 patent/US20100267682A1/en not_active Abandoned
- 2008-10-15 EP EP08848076A patent/EP2222286A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100096077A (ko) | 2010-09-01 |
| BRPI0820338A2 (pt) | 2017-05-02 |
| CA2703792A1 (en) | 2009-05-14 |
| CN101848708A (zh) | 2010-09-29 |
| AU2008325016A1 (en) | 2009-05-14 |
| US20100267682A1 (en) | 2010-10-21 |
| CN101848708B (zh) | 2013-01-02 |
| JP2011503075A (ja) | 2011-01-27 |
| WO2009061587A1 (en) | 2009-05-14 |
| MX2010005119A (es) | 2010-05-27 |
| EP2222286A1 (en) | 2010-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240238298A1 (en) | JAK Inhibitors for Managing Conditions in Patients with Down's Syndrome or Other Trisomy | |
| JP5543956B2 (ja) | 癌の処置のための方法および組成物 | |
| JP6440212B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| JP2011511071A5 (enExample) | ||
| MX2023005533A (es) | Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina. | |
| MXPA05007857A (es) | Moduladores derivados de indol de receptores nucleares de hormonas esteroideas. | |
| WO2010081817A1 (en) | Method for treating colorectal cancer | |
| US20100093754A1 (en) | Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual Disorders | |
| CY1108309T1 (el) | Διαμορφωτες πυρηνικων υποδοχεων τρικυκλικων στεροειδων ορμονων | |
| JP2011503075A5 (enExample) | ||
| JP2009542623A (ja) | Ｈ２遮断薬、少なくとも１つの抗炎症薬剤および細胞毒性薬剤を含む抗がん治療 | |
| JP2017519775A5 (enExample) | ||
| JP2011503075A (ja) | エポチロンまたはエポチロン誘導体誘発下痢を処置するためのコルチコステロイド | |
| CN102065865A (zh) | 多发性骨髓瘤治疗 | |
| JP2021502392A5 (enExample) | ||
| EP2670405B1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| WO2001060370A1 (en) | Remedies for endothelin-induced diseases | |
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| CN114599352A (zh) | 用于治疗癌症的α-甲基-DL-酪氨酸烷基酯 | |
| KR20200014880A (ko) | 테세탁셀 및 카페시타빈에 대한 투약 일정 | |
| JP2022531570A5 (enExample) | ||
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| CN111629727A (zh) | 用于治疗血液肿瘤和实体癌的钙释放活化钙通道调节剂 | |
| WO2022007878A1 (zh) | β-1肾上腺素受体拮抗剂用于制备减少表皮生长因子受体抑制剂诱导的上皮细胞损伤以及抑制癌细胞的组合物的用途 | |
| JP2010526073A (ja) | 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130426 |